Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Newswire

Comprehensive Real-Time News Feed for Teva Pharmaceutical Industries.

Results 1 - 20 of 671 in Teva Pharmaceutical Industries

  1. Report Published: "Raynauds Disease - Pipeline Review, H1 2015"Read the original story

    23 hrs ago | PR-inside.com

    ... Bayer AG, Human Stem Cells Institute, Mezzion Pharma Co. Ltd., Nippon Shinyaku Co., Ltd., Teva Pharmaceutical Industries Limited About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market ...

    Comment?

  2. How Much is Actavis Worth? A Lot More Than It is NowRead the original story w/Photo

    Friday May 22 | Barron's

    JPmorgan's Chris Schott and team think there is "compelling valuation upside" in Actavis' shares, especially following Teva Pharmaceutical's big for Mylan . They explain why: remains our top pick, driven by a combination of strong organic growth , a range of upside drivers to estimates , and inexpensive valuation.

    Comment?

  3. Xenon Pharmaceuticals Inc. Appoints To Its Board Of DirectorsRead the original story

    Thursday May 21 | BioSpace

    Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, today announced that Steven Gannon has been appointed to its Board of Directors, where he will also serve on the Company's Audit Committee. Mr. Gannon is a highly respected senior financial executive whose executive and board experience spans the pharmaceutical industry, and includes corporate finance and strategic transactions, mergers and acquisitions, business and corporate development and commercial operations.

    Comment?

  4. Energy Stocks Dominating Billionaire Izzy Englander's Top Holdings: ...Read the original story w/Photo

    Thursday May 21 | Insider Monkey

    ... discretionary being among the primary investment sectors of the billionaire money manager. Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ), NextEra Energy Inc (NYSE: NEE ) and American Electric Power Company Inc (NYSE: AEP ) are among the top ...

    Comment?

  5. Endo To Purchase Par PharmaceuticalsRead the original story

    Thursday May 21 | Chemical and Engineering News

    ... The generic drug area has been rife with merger and acquisition moves. The most recent one is Teva Pharmaceutical Industries' hostile $40 billion bid for Mylan . At the same time, Mylan has been pursuing an acquisition of Perrigo , which has ...

    Comment?

  6. Endo International Acquires Par Pharmaceuticals For $8 BillionRead the original story

    Thursday May 21 | GuruFocus.com

    ... the companies doing business in the said industry. For instance, number one generic drugmaker Teva Pharmaceutical Industries Ltd ( TEVA ) made a bid of $43 billion for Mylan ( MYL ), which in turn is trying to takeover Perrigo Co. Plc. ( PRGO ). The ...

    Comment?

  7. TARO: Yes, We Have A WinnerRead the original story w/Photo

    Wednesday May 20 | Seeking Alpha

    Although Taro's revenue growth has slowed in recent years, it looks like it will pick up again in the next few years. There are a number of risks associated with Taro's size and industry, but I'm betting on good management.

    Comment?

  8. Temperature Poll: Will Mylan Buy Teva, As Predator Becomes Prey?Read the original story

    Monday May 18 | BioSpace

    May 19, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Will Mylan Buy Teva, As Predator Becomes Prey? The complicated three-way takeover waltz being conducted between Pittsburgh, Penn.-based Mylan Inc. , Israeli company Teva Pharmaceutical Industries Ltd. and Perrigo Company took another weird turn last week, after Mylan said that while it still views Teva's unsolicited $40.1 billion bid as too low, it might want to acquire Teva itself eventually. Mylan Chairman Robert J. Coury made it clear that if Mylan is able to cement its deal with Perrigo, it might go shopping again-and this time to buy Teva, not be bought.

    Comment?

  9. Endo To Purchase Par PharmaceuticalRead the original story w/Photo

    Monday May 18 | Chemical and Engineering News

    ... drug area has been rife with merger and acquisition moves. The most recent one has been Teva Pharmaceutical Industries hostile $40 billion bid for Mylan . In contrast, the Endo-Par transaction has been unanimously approved by the boards of the two ...

    Comment?

  10. TevaTo Present New Respiratory Data At 2015 Annual International...Read the original story

    Thursday May 14 | BioSpace

    Teva Pharmaceutical Industries Ltd., today announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19, 2015, Help employers find you! Check out all the jobs and post your resume .

    Comment?

  11. Why Shorting Opko Health Makes No Sense After The Q1 2015 Earnings ReportRead the original story w/Photo

    Friday May 15 | Seeking Alpha

    The Q1 2015 earnings report confirmed key developments related to 4Kscore Test reimbursement and NDA filing for Rayaldee, and the market is taking notice. I previously wrote a piece on Opko, featuring its various developments in point-of-care diagnostics, novel molecular diagnostics, and pharmaceuticals and vaccines.

    Comment?

  12. Teva Pharmaceutical Industries - An International Growth StoryRead the original story w/Photo

    Friday May 15 | Seeking Alpha

    Most companies listed on US stock exchanges are "home-grown" stories which are founded in the United States. The typical path for these companies is to grow to a point where they need additional funds quickly, then list on a public stock exchange like the New York Stock Exchange or NASDAQ in order to attract investors' funds to help finance their future growth.

    Comment?

  13. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Friday May 15 | Business Wire

    )--Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society (ATS) In... )--FoxwoodsA Resort Casino has reported slot revenue of $38.7 million for ...

    Comment?

  14. U.S. Loves Europe As Pharma, Energy Boost M&ARead the original story w/Photo

    Thursday May 14 | Investor's Business Daily

    Cross-border mergers and acquisitions worldwide this year totaled $593.6 billion as of Thursday, up 29% from a year ago and the biggest year-to-date total since 2007, according to Thomson Reuters. Announced cross-border deals comprise 43% of total M&A so far in '15, the largest annual share since '07, when cross-border transactions amounted to 45% of all M&A.

    Comment?

  15. Teva Presents Further Data From Phase IIb With TEV-48125 In Chronic...Read the original story

    Wednesday May 13 | BioSpace

    Teva Presents Further Data From Phase IIb With TEV-48125 In Chronic Migraine At The International Headache Society Congress : Efficacy And Safety Results At All Doses And Endpoints Present Robust Case For Progression To Phase III Both doses of TEV-48125 demonstrated statistically significant reduction in the number of headache hours after just one week More than half of the patients in each dose group experienced a 50% or more decrease in headache frequency to episodic migraine JERUSALEM-- --Teva Pharmaceutical Industries Ltd. announced the presentation of further data from its chronic migraine phase 2b study evaluating the efficacy and safety, versus placebo, of two doses of TEV-48125, an anti-calcitonin gene-related peptide ligand monoclonal antibody.

    Comment?

  16. Morningstar Assigns "A-" Credit Rating to Teva Pharmaceutical IndustriesRead the original story w/Photo

    Thursday May 14 | AmericanBankingNews.com

    Teva Pharmaceutical Industries has earned an "A-" credit rating from Morningstar . The firm's "A-" rating indicates that the company is a low default risk.

    Comment?

  17. Developer of needle-free, drug-delivery technologies raises $46MRead the original story w/Photo

    Wednesday May 13 | Business Journal

    ... injector for the acute treatment of migraines. The company has a multiproduct deal with Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA). Teva, based in Israel, has its North American headquarters in North Wales, Pa. Piper Jaffray & Co. was the ...

    Comment?

  18. Celgene's Revlimid Patent Families Do Not Appear To Meet Criteria For ProtectionRead the original story w/Photo

    Wednesday May 13 | Seeking Alpha

    ... forms of Celgene's drug Revlimid (lenalidomide). On May 7, 2015, attorneys from Celgene, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ), and Mylan N.V. (NASDAQ: MYL ) argued the novelty and obviousness of the '682 patent and the patent was ...

    Comment?

  19. Pfizer Will Make $120 Billion Bid for GlaxoSmithKline in Second Quarter, Says PollRead the original story

    Tuesday May 12 | BioSpace

    ... at Pfizer Inc. (PFE) pushed Chief Executive Officer Ian Read to approach Israeli drug company Teva Pharmaceutical Industries Ltd. ( TEVA ) at the end of 2014 about a possible merger, people familiar with the matter told Bloomberg News at the end of ...

    Comment?

  20. Xenon Pharmaceuticals Inc. Reports First Quarter 2015 Financial...Read the original story

    Tuesday May 12 | BioSpace

    ... in 2016 and identifying novel target using our Extreme Genetics platform." Xenon's partner Teva Pharmaceutical Industries Ltd. is conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial for TV-45070 in osteoarthritis. ...

    Comment?